29 October 2026 · 15 min read

Methylene Blue and Arterial Function: What the Pharmacology and the Human Studies Actually Show

Executive summary

  • Methaemoglobinaemia is what methylene blue is approved for as an injectable treatment. The argument for using methylene blue as a regular supplement relies on its function as a substitute electron transporter in separated mitochondria.
  • The medication blocks the nitric oxide mechanism, which signals the artery wall to relax, in animal blood vessels and cultured cells.
  • In patients experiencing vasodilatory shock who are in hospital, the mechanism is administered intravenously to increase blood pressure, with a meta-analysis indicating potential survival benefits in such cases.
  • Methylene blue and its primary metabolite block the monoamine oxidase A enzyme at nanomolar levels in isolated lab tests, but disrupting the nitric oxide pathway requires micromolar concentrations.
  • Brain imaging studies in humans have reported enhancements in brain imaging responses and one memory assessment, alongside decreases in brain blood flow and brain oxygen metabolism.
  • Serotonin toxicity stands as the most thoroughly documented risk in humans when this drug is combined with serotonergic antidepressants. G6PD deficiency presents a known issue, but the level of risk differs depending on the variant. Small oral doses administered briefly for diagnostic purposes seem to be generally well tolerated.
  • The primary analyses published from a trial programme involving approximately 2,500 patients with dementia or cognitive impairment, which tested a similar compound, indicated no advantage at the pre-established endpoints, a finding the sponsor contests.
  • The unregulated supplements' low doses might primarily function as monoamine oxidase inhibitors, rather than affecting the artery wall, although this wasn't assessed. That’s my best interpretation at the moment, though I’m willing to consider any contrary evidence that may come to light.

I operate a private clinic where I provide consultations for a fee. I do not have any commercial ties to methylene blue, as I neither sell it nor prescribe it through any programme, nor do I gain financially from any connection to it. I usually prefer promoting fundamental lifestyle practices rather than endorsing supplements that lack proof, and I remain doubtful about unregulated daily interventions. This shapes my interpretation of the methylene blue research, a substance approved for methaemoglobinaemia treatment via injection yet, by October 2026, increasingly marketed online as a daily wellness product.

The rationale behind daily usage is largely based on mitochondria, whereas concerns are centred on arteries. This article examines the findings from pharmacology research and human trials. The article does not provide dosing advice, nor does it endorse self-dosing, and it definitely does not suggest discontinuing or altering any prescribed medication.

The mitochondrial argument

The supplement’s foundational rationale is rooted in mitochondrial function. The compound underwent evaluation in guinea pig brain mitochondria samples, with dosage levels ranging between 100 nanomoles per litre and 1 micromole per litre (Ref 1). The researchers found that resting oxygen consumption rose, and when they intentionally disrupted electron flow with complex I or complex III inhibitors, the drug both boosted ATP production moderately yet significantly and reinstated the mitochondrial membrane potential.

According to the authors, this finding aligns with the drug transporting electrons from upstream regions of the electron transport chain to cytochrome c, akin to a detour route activated when the primary pathway is obstructed. The study also reported that the drug significantly raised hydrogen peroxide levels in every scenario tested and reduced its breakdown. The findings came from animal tissue in a dish, not live humans, so the results for humans might vary, and blood vessels were not examined.

The nitric oxide signal in the artery wall

Nitric oxide, released by the endothelium that lines artery walls, acts as a signal prompting nearby smooth muscle to relax. Nitric oxide serves the role of a chemical text message, with the enzyme soluble guanylate cyclase operating as the phone that detects it, generating cyclic GMP to prompt relaxation.

In an investigation from 1981 conducted on isolated bovine coronary artery tissue, methylene blue was found to suppress the relaxation effects induced by nitroglycerin, sodium nitrite and amyl nitrite, as well as their ability to activate guanylate cyclase (Ref 2). In a subsequent in-vitro investigation involving isolated blood vessels, cultured endothelial cells, and purified enzymes, researchers found that the drug directly inhibits nitric oxide synthase, the enzyme responsible for producing the initial signal (Ref 3). The drug fully blocked L-citrulline production by isolated nitric oxide synthase at a concentration of 30 micromolar. This study also revealed that the compound was a significantly less potent inhibitor of guanylyl cyclase, the receptor, achieving 50 per cent inhibition around 60 micromolar, thereby addressing the common oversimplification that methylene blue merely "blocks guanylate cyclase". These long-established animal and cell culture models, not human trials, demonstrate the drug's use as a lab tool to deactivate the nitric oxide-mediated relaxation process.

The concentration question and monoamine oxidase

The difference between a lab-based process and a human supplement hinges on the concentration levels. The research mentioned earlier found that the half-maximal inhibitory concentration ranged from 5.3 to 9.2 micromolar for nitric oxide synthase, whereas guanylyl cyclase required approximately 60 micromolar to achieve half inhibition (Ref 3).

Methylene blue acts as a strong, reversible in vitro inhibitor of monoamine oxidase A, an enzyme responsible for metabolising neurotransmitters like serotonin (Ref 4). Monoamine oxidase A in recombinant human enzyme assays had a half-maximal inhibitory concentration of 70 nanomolar when inhibited by methylene blue (Ref 5). Azure B, its main metabolite, had approximately sixfold greater potency, with a half-maximal inhibitory concentration of 11 nanomolar. The effect might persist beyond the dosage since the metabolite acts as a stronger inhibitor, even though the study does not determine its duration in humans.

The assertion that it does not enter the bloodstream upon ingestion is incorrect. The study measured the absorption of a 500 milligram oral dose in sixteen healthy individuals, finding an average absolute bioavailability of approximately 72 per cent (Ref 6). The single dose was much higher than typical supplement doses, and no assessment of artery function was conducted. I have yet to come across research that examines blood or tissue concentrations following small, supplement-level oral doses.

Separate in-vitro assays showed that monoamine oxidase A inhibition happened at nanomolar concentrations, while nitric oxide pathway inhibition required micromolar levels. This suggests that supplement doses may primarily target monoamine oxidase A, potentially without affecting the nitric oxide pathway, although this specific interaction was not directly measured. Given that the assays differed, the ratio is not exact. As far as I know, this remains an assumption, and I’m willing to review any contradictory data.

What human studies show at the brain and blood-vessel level

A randomised, double-blind, placebo-controlled study with 26 healthy adults found that one oral dose enhanced functional magnetic resonance imaging activity in the bilateral insular cortex during both a vigilance task and a short-term memory task (Ref 7). A 7 per cent rise in accurate answers during the recall phase was also linked to this. Though the authors refer to their dose as low, the abstract fails to specify the milligram amount. This study involved a one-time administration to a limited sample of healthy adults, evaluated after one hour using imaging substitutes instead of clinically meaningful endpoints, with the memory outcome representing just one of multiple assessed metrics.

The same team published another study with a comparable approach, finding decreased blood flow in a task-specific network during a visuomotor task and heightened resting-state functional connectivity (Ref 8). As connectivity measures altered, blood flow in that network decreased. The mere presence of a decline in a specific area during an activity does not constitute proof of vascular damage.

An additional neuroimaging study assessed blood flow more precisely in healthy humans administered intravenous doses. The lower and higher doses led to a decrease in overall cerebral blood flow, with a significant drop observed in the cerebral metabolic rate of oxygen (Ref 9). Animal evidence from a rat arm also demonstrated decreased blood flow and reduced glucose metabolism in the brain. The findings ran counter to the authors' expectations, while acknowledging that healthy individuals might already exhibit minimal potential for metabolic enhancement. They propose hormesis as a potential explanation, where higher concentrations might inhibit instead of enhance; this is merely their proposal rather than a confirmed finding, and intravenous administration differs from oral supplements. However, even within the most relevant human data I've encountered, both blood flow and oxygen metabolism decreased.

Clinical vasoplegia and where the argument could be wrong

Evidence most strongly opposing a straightforward "methylene blue harms arteries" narrative originates in intensive care settings, as it is intentionally administered there to narrow abnormally widened vessels during vasodilatory shock. The drug increased mean arterial pressure and systemic vascular resistance in a meta-analysis of 11 randomised trials involving 556 seriously ill or perioperative patients, while in the nine trials examining mortality, it showed a connection to reduced mortality rates (Ref 10). The drug's effects align with intentional blockade of the nitric oxide pathway. The studies involved small samples and intravenous dosing under hospital supervision, and the authors advocate for bigger trials. The mechanism clearly serves a purpose in clinical settings, although it cannot be applied to healthy individuals consuming it orally.

Human vascular responses appear to differ based on the dosage and mode of administration. In a limited, open-label study involving ten individuals with critical septic shock and lacking a control group, administering an intravenous hospital dose boosted systemic vascular resistance while simultaneously heightening pulmonary vascular resistance and worsening gas exchange (Ref 11).

The concentration could potentially influence the direction of the effect. In a study using thoracic aortic rings from diabetic rats outside the body, a minimal concentration of 0.1 micromolar partly reversed the heightened contraction, the reduced endothelium-dependent relaxation, and the elevated hydrogen peroxide production in vessels with an undamaged endothelium (Ref 12). The half-maximal concentrations for nitric oxide synthase inhibition reported previously are higher than that concentration. Even though this result is limited to a single tissue sample from an animal in a dish and not from a human trial, it implies that the effect on vessels could be reversed at very low levels of exposure. For now, this is how I understand it, but I'm receptive to evidence that contradicts it.

Safety signals in human data

The drug's ability to inhibit monoamine oxidase is most clearly linked to the risk of serotonin toxicity. A systematic review found 50 distinct documented instances of serotonin syndrome linked to methylene blue, with symptoms varying from minor to one recorded death (Ref 13). The 50 cases all included the use of serotonergic antidepressants simultaneously, and the majority involved intravenous administration during parathyroid surgery or in cases of vasoplegic shock. The authors describe their own case, though, where the issue arose after taking an oral methylene blue urinary analgesic in a patient using multiple serotonergic medications, indicating oral formulations may also lead to this outcome. Incidence rates can't be derived from case reports, however. A retrospective single-centre study involving 193 patients who underwent parathyroid surgery revealed that 12 experienced postoperative neurological issues, all of whom were on a serotonin reuptake inhibitor, whereas 8.8 per cent of the unaffected patients were (Ref 14). The abstract refers to the condition as toxic metabolic encephalopathy instead of confirmed serotonin syndrome, describing an association that aligns with in-vitro pharmacology.

A systematic review analysing 1,902 individuals who were given oral methylene blue as a dye during swallowing tests documented three significant adverse incidents linked to it, equating to 0.16 per cent (Ref 15). Despite brief oral exposure generally being well tolerated, this information provides limited insight into its effects with daily use or when combined with other medications.

Glucose-6-phosphate dehydrogenase (G6PD) deficiency poses a known issue for this medication, with the risk evidence differing depending on the variant. A clinical trial involved 74 adult men in Burkina Faso who had G6PD deficiency but were otherwise healthy, and they were given a three-day oral treatment of methylene blue and chloroquine (Ref 16). No haemolysis was observed, and participants tolerated the regimen well. The study lacked a comparison group, featured exclusively male participants, and the authors limited their findings to mainly class III deficiency, a less severe form. The risk varies among different variants, though this finding cannot be extended to all of them.

What the large trials found

The biggest studies examined a similar compound, a stable reduced version of the methylthioninium molecule, in individuals with dementia or cognitive decline. The sponsor's phase 3 programme, consisting of four trials with approximately 2,500 patients, failed to demonstrate any benefit at the prespecified endpoints in the published primary analyses. The two trials focused on Alzheimer's disease collectively enrolled 1,686 participants, with the authors reporting a negative primary analysis in the trial involving 891 patients (Ref 17, Ref 18). In the study involving 220 individuals with behavioural variant frontotemporal dementia, the randomised doses showed no significant differences (Ref 19). The study involving 598 participants showed that significant differences in the co-primary endpoints at 52 weeks could not be established, an outcome the authors link to symptomatic effects observed in the control group (Ref 20). Among those with mild cognitive impairment, significant variations in cognitive deterioration appeared at 78 and 104 weeks when comparing early and delayed treatment initiation. Subgroup and delayed-start analyses conducted later are more susceptible to bias compared to a primary endpoint, and at best, they can only propose hypotheses.

The sponsor challenges the way the negative primary analyses have been understood. The sponsor contends that the low dose administered in the control group, intended to preserve blinding by altering urine colour, exhibited its own pharmacological effects (Ref 18). A study on population pharmacokinetics, conducted by authors affiliated with the sponsor, also supports this claim, indicating that time-varying clearance resulted in plasma levels from the control dose exceeding expectations (Ref 21). It’s difficult to either verify or dispute this active-control claim within a study structured like this. These trials employed a distinct chemical composition and dosages in dementia patients, thereby failing to assess the effects of over-the-counter supplements on healthy adults.

What this means in practice

I'm unable to view you on the screen, and I'm unaware of your intake or your medical background. Before doing anything involving methylene blue, consult with the person who prescribes your medication, and avoid stopping or altering a prescribed medicine based solely on this article's content. From a pharmacology perspective, there are a few questions your prescriber should address, such as whether any of the medications you take, including over-the-counter and cough remedies, are serotonergic, whether your G6PD status is confirmed, and if a monoamine oxidase inhibitor would be safe with your current treatments. General practitioners adhere to recognised protocols, making it reasonable to request them to assess your medications for serotonergic interactions.

Nitric oxide can be produced through mechanisms other than medication. A small randomised study with 24 healthy participants showed that exposing skin to ultraviolet A light reduced blood pressure, and that treating the forearm enhanced blood flow without relying on the nitric oxide synthase enzyme (Ref 22). The authors propose that this releases pre-existing nitric oxide reserves located in the upper layers of the skin. This was a brief trial, not a therapy for heart health, and ultraviolet light is recognised to pose risks of skin harm.

From my standpoint, which is a lifestyle-oriented viewpoint not examined in the studies above, arterial health is built on essential foundational measures. For my part, tackling physiological insulin resistance, ensuring good sleep and engaging your muscles are my priorities over any chemical solution.

Disclosures

I operate a private clinic, provide consultations for a fee, and lead a paid community group, which means I have a financial stake in readers valuing this type of analysis. I approach the editorial content with a preference for fundamental lifestyle practices instead of untested supplements, leading me to scrutinise the unregulated supplement industry. Methylene blue does not present any financial benefit for me. I sought to balance my viewpoint by referring to the clinical application of the drug in vasodilatory shock and the sponsor’s statements on the phase 3 trials, instead of solely highlighting the negative findings. Several of the trial papers mentioned were either funded or written by TauRx Therapeutics, the sponsor, or its hired parties (Refs 17 to 21).

This article does not provide personalised medical advice, and it should not replace the recommendations of your healthcare professional. I provide consultations to assist you in applying this information to your specific situation, although numerous skilled clinicians already cover this area extensively, so you are under no obligation to consult with me.

References

  1. Tretter L, Horvath G, Hölgyesi A, et al. Enhanced hydrogen peroxide generation accompanies the beneficial bioenergetic effects of methylene blue in isolated brain mitochondria. Free Radic Biol Med. 2014. PMID: 25277417. https://doi.org/10.1016/j.freeradbiomed.2014.09.024
  2. Gruetter CA, Kadowitz PJ, Ignarro LJ. Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium nitrite, and amyl nitrite. Can J Physiol Pharmacol. 1981. PMID: 6112057. https://doi.org/10.1139/y81-025
  3. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol. 1993. PMID: 7679577. https://doi.org/10.1016/0006-2952(93)90072-5
  4. Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol. 2007. PMID: 17721552. https://doi.org/10.1038/sj.bjp.0707430
  5. Petzer A, Harvey BH, Wegener G, Petzer JP. Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase. Toxicol Appl Pharmacol. 2012. PMID: 22197611. https://doi.org/10.1016/j.taap.2011.12.005
  6. Walter-Sack I, Rengelshausen J, Oberwittler H, et al. High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol. 2009. PMID: 18810398. https://doi.org/10.1007/s00228-008-0563-x
  7. Rodriguez P, Zhou W, Barrett DW, et al. Multimodal randomized functional MR imaging of the effects of methylene blue in the human brain. Radiology. 2016. PMID: 27351678. https://doi.org/10.1148/radiol.2016152893
  8. Rodriguez P, Singh AP, Malloy KE, et al. Methylene blue modulates functional connectivity in the human brain. Brain Imaging Behav. 2017. PMID: 26961091. https://doi.org/10.1007/s11682-016-9541-6
  9. Singh N, MacNicol E, DiPasquale O, et al. The effects of acute methylene blue administration on cerebral blood flow and metabolism in humans and rats. J Cereb Blood Flow Metab. 2023. PMID: 36803299. https://doi.org/10.1177/0271678X231157958
  10. Pruna A, Bonaccorso A, Belletti A, et al. Methylene blue reduces mortality in critically ill and perioperative patients: a meta-analysis of randomized trials. J Cardiothorac Vasc Anesth. 2024. PMID: 37880041. https://doi.org/10.1053/j.jvca.2023.09.037
  11. Weingartner R, Oliveira E, Oliveira ES, et al. Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue. Braz J Med Biol Res. 1999. PMID: 10585632. https://doi.org/10.1590/s0100-879x1999001200009
  12. Privistirescu AI, Sima A, Duicu OM, et al. Methylene blue alleviates endothelial dysfunction and reduces oxidative stress in aortas from diabetic rats. Can J Physiol Pharmacol. 2018. PMID: 29894646. https://doi.org/10.1139/cjpp-2018-0119
  13. Zuschlag ZD, Warren MW, Schultz SK. Serotonin toxicity and urinary analgesics: a case report and systematic literature review of methylene blue-induced serotonin syndrome. Psychosomatics. 2018. PMID: 30104021. https://doi.org/10.1016/j.psym.2018.06.012
  14. Kartha SS, Chacko CE, Bumpous JM, et al. Toxic metabolic encephalopathy after parathyroidectomy with methylene blue localization. Otolaryngol Head Neck Surg. 2006. PMID: 17071309. https://doi.org/10.1016/j.otohns.2006.05.026
  15. Tariq B, Simon SR, Pilz W, et al. Evaluating the safety of oral methylene blue during swallowing assessment: a systematic review. Eur Arch Otorhinolaryngol. 2021. PMID: 33389001. https://doi.org/10.1007/s00405-020-06509-3
  16. Mandi G, Witte S, Meissner P, et al. Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso. Trop Med Int Health. 2005. PMID: 15655011. https://doi.org/10.1111/j.1365-3156.2004.01356.x
  17. Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016. PMID: 27863809. https://doi.org/10.1016/S0140-6736(16)31275-2
  18. Schelter BO, Shiells H, Baddeley TC, et al. Concentration-dependent activity of hydromethylthionine on cognitive decline and brain atrophy in mild to moderate Alzheimer's disease. J Alzheimers Dis. 2019. PMID: 31658058. https://doi.org/10.3233/JAD-190772
  19. Shiells H, Schelter BO, Bentham P, et al. Concentration-dependent activity of hydromethylthionine on clinical decline and brain atrophy in a randomized controlled trial in behavioral variant frontotemporal dementia. J Alzheimers Dis. 2020. PMID: 32280089. https://doi.org/10.3233/JAD-191173
  20. Wischik CM, Stefanacci R, Bentham P, et al. Clinical, imaging and blood biomarker outcomes in a phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease. J Prev Alzheimers Dis. 2026. PMID: 41570392. https://doi.org/10.1016/j.tjpad.2026.100480
  21. van Maanen E, Gonçalves A, Chen L, et al. Atypical population pharmacokinetics of hydromethylthionine in patients with Alzheimer's disease explains unexpected phase 3 trial results. Br J Clin Pharmacol. 2026. PMID: 41917677. https://doi.org/10.1002/bcp.70539
  22. Liu D, Fernandez BO, Hamilton A, et al. UVA irradiation of human skin vasodilates arterial vasculature and lowers blood pressure independently of nitric oxide synthase. J Invest Dermatol. 2014. PMID: 24445737. https://doi.org/10.1038/jid.2014.27